BridgeBio Pharma (BBIO) News Today $40.47 -0.67 (-1.63%) As of 01:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BBIO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Wolfe ResearchWolfe Research began coverage on shares of BridgeBio Pharma in a report on Tuesday. They set an "outperform" rating and a $49.00 target price on the stock.June 17 at 8:43 AM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Hits New 52-Week High - Here's What HappenedBridgeBio Pharma (NASDAQ:BBIO) Sets New 52-Week High - What's Next?June 17 at 5:03 AM | marketbeat.comGAMMA Investing LLC Boosts Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)GAMMA Investing LLC increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 5,811.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,804 shares of the company's stock afJune 16 at 3:02 AM | marketbeat.comAssenagon Asset Management S.A. Buys 1,096,799 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Assenagon Asset Management S.A. increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 4,544.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,120,933 shares of the company's stock afJune 13, 2025 | marketbeat.comQ2 EPS Estimate for BridgeBio Pharma Increased by AnalystJune 13, 2025 | americanbankingnews.comBridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. WainwrightJune 11, 2025 | insidermonkey.comBridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. WainwrightJune 11, 2025 | msn.comHannah Valantine Sells 4,292 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 4,292 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $40.00, for a total value of $171,680.00. Following the completion of the sale, the director now directly owns 1,764 shares of the company's stock, valued at $70,560. This trade represents a 70.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.June 11, 2025 | marketbeat.comCantor Fitzgerald Estimates BBIO FY2026 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer foreJune 11, 2025 | marketbeat.comHC Wainwright Boosts Earnings Estimates for BridgeBio PharmaBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Analysts at HC Wainwright raised their Q2 2025 earnings per share estimates for shares of BridgeBio Pharma in a report issued on Monday, June 9th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.87) perJune 11, 2025 | marketbeat.comHC Wainwright Increases BridgeBio Pharma (NASDAQ:BBIO) Price Target to $56.00June 11, 2025 | americanbankingnews.comHC Wainwright Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock PriceHC Wainwright increased their target price on shares of BridgeBio Pharma from $53.00 to $56.00 and gave the company a "buy" rating in a research report on Monday.June 9, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Moss Adams Wealth Advisors LLCMoss Adams Wealth Advisors LLC increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 113.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,202 shares of the company's stock after purchasing anJune 9, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month High - Here's What HappenedJune 8, 2025 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Stock Rating Upgraded by Wall Street ZenJune 8, 2025 | americanbankingnews.comBrokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) Target Price at $57.09June 8, 2025 | americanbankingnews.comWall Street Zen Upgrades BridgeBio Pharma (NASDAQ:BBIO) to HoldWall Street Zen upgraded shares of BridgeBio Pharma from a "sell" rating to a "hold" rating in a research report on Saturday.June 7, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High - Here's What HappenedBridgeBio Pharma (NASDAQ:BBIO) Sets New 1-Year High - Here's What HappenedJune 6, 2025 | marketbeat.comCalifornia State Teachers Retirement System Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)California State Teachers Retirement System lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 6.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 115,655 shares of the company's stock after buJune 5, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Rating of "Moderate Buy" from BrokeragesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eleven have isJune 5, 2025 | marketbeat.comBMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying CompetitionJune 4, 2025 | msn.comBridgeBio: New Data Bolsters The Bull CaseJune 4, 2025 | seekingalpha.comBridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025June 2, 2025 | globenewswire.comBridgeBio Pharma (NASDAQ:BBIO) Downgraded by Wall Street Zen to "Sell"Wall Street Zen cut shares of BridgeBio Pharma from a "hold" rating to a "sell" rating in a report on Friday.June 1, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 36.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 609,588 shares of thMay 30, 2025 | marketbeat.comNuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Nuveen Asset Management LLC lowered its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 96.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 402,926 shares of the company's stock after selMay 29, 2025 | marketbeat.com185,000 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Purchased by Jefferies Financial Group Inc.Jefferies Financial Group Inc. purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 185,000 shares of the company's stock, valuedMay 28, 2025 | marketbeat.comTwo Sigma Investments LP Has $6.55 Million Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Two Sigma Investments LP lowered its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 238,536 shares of the company's stock after selling 142,706 sharesMay 28, 2025 | marketbeat.comCetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Cetera Investment Advisers acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 37,163 shares of the companMay 26, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Position Raised by ProShare Advisors LLCProShare Advisors LLC increased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 28.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,539 shares of the company's stock aftMay 24, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Buys 40,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Frazier Life Sciences Management L.P. boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,800,457 shares of the company's stMay 23, 2025 | marketbeat.comWoodline Partners LP Raises Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Woodline Partners LP raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 132.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,211,521 shares of the company'sMay 22, 2025 | marketbeat.comZimmer Partners LP Acquires New Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Zimmer Partners LP purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 180,400 shares of the company's stock, valued at approximatMay 22, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $871,779.48 in StockMay 21, 2025 | insidertrades.comBridgeBio’s Acoramidis: A Breakthrough in ATTR-CM TreatmentMay 21, 2025 | insidermonkey.comAcoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CMMay 20, 2025 | globenewswire.comTema Etfs LLC Invests $3.90 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Tema Etfs LLC acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 141,972 shares of the company's stock, valued at approximately $3,896,000. BridgeBio Pharma coMay 20, 2025 | marketbeat.comEarly and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM StudyMay 19, 2025 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Sphera Funds Management LTD.Sphera Funds Management LTD. lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 7.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 905,279 shares of the company's stock after acqMay 18, 2025 | marketbeat.comProsight Management LP Sells 91,810 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Prosight Management LP cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 995,000 shares of the company's stock after sMay 17, 2025 | marketbeat.comNicholas Investment Partners LP Has $1.64 Million Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Nicholas Investment Partners LP boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 68.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 59,892 shares of the company's stock after acquiriMay 16, 2025 | marketbeat.comOctagon Capital Advisors LP Reduces Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Octagon Capital Advisors LP lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 20.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 441,600 shares of the company's stock after sellingMay 15, 2025 | marketbeat.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells 6,000,000 Shares of StockMay 15, 2025 | insidertrades.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Janus Henderson Group PLCJanus Henderson Group PLC grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,907,533 shares of the company's stock after buying an additioMay 15, 2025 | marketbeat.comJefferies Financial Group Inc. Invests $5.08 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Jefferies Financial Group Inc. acquired a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 185,000 shares of the company's stock, valued at approximately $5,076,000May 15, 2025 | marketbeat.com112,535 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Hudson Bay Capital Management LPHudson Bay Capital Management LP bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 112,535 shares of the company's stoMay 15, 2025 | marketbeat.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 14, 2025 | globenewswire.comWhy BridgeBio Pharma, Inc. (BBIO) Declined on TuesdayMay 14, 2025 | finance.yahoo.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) is Lion Point Capital LP's 6th Largest PositionLion Point Capital LP lessened its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 17.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,300 shares of the company's stock after sellMay 14, 2025 | marketbeat.comBridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025May 14, 2025 | nasdaq.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼1.050.90▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼209▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beigene News BioNTech News Teva Pharmaceutical Industries News Summit Therapeutics News Genmab A/S News Intra-Cellular Therapies News Dr. Reddy's Laboratories News Ascendis Pharma A/S News Viatris News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BBIO Stock Free BBIO Stock Alerts